4.0
Jan 22, 2024
Current employee, more than 3 years
Kuala Lumpur
Recommend
CEO approval
Business Outlook
Pros
Career progression, diverse inclusive culture,
Cons
Frequent company restructuring, commission wise not as competitive as other pharma company